Drug manufacturing license breaks bottleneck

Hu Min
License issued to Anbison Lab will allow it to participate in bidding and procurement, and let it enjoy some preferential policies, according to the Shanghai Drug Administration.
Hu Min
Drug manufacturing license breaks bottleneck
Chen Xihan

Zhang Qing (right), deputy director of the Shanghai Drug Administration, grants the drug manufacturing license to a representative from Anbison Lab.

The first drug manufacturing license for drug research institutes in China was issued by Shanghai's drug watchdog on Wednesday, breaking the bottleneck of drug research institutes in the participation of medicine bidding and procurement.

Some provinces require drug research institutes to obtain the license before they are allowed to participate in bidding and procurement, leaving them unable to enjoy some preferential policies, the Shanghai Drug Administration said.

The first license was issued to Anbison Lab.

"The reform will stimulate the innovation vitality of biomedicine companies," said Zhang Qing, deputy director of the administration.

Applications for drug manufacturing license from nine drug research institutes in Shanghai are being reviewed, according to the administration.

Special Reports
Top